Stock Market News
Angle reaches provisional agreement with Abbott
Medical diagnostics group Angle inked a deal with US healthcare firm Abbott on Tuesday, with the latter agreeing to provide Angle with its proprietary PathVysion HER-2 DNA FISH probe kits for its ANG-002 Federal Drug Administration study.
Fluorescence in situ hybridisation analysis, or FISH, is a form of investigating the cancer cells used with solid tissue biopsy to help select treatment and is one of Angle's exploratory end-points for its study into metastatic breast cancer.
Angle hopes to demonstrate that circulating tumour cells (CTCs) can be harvested from the blood of metastatic breast cancer patients using its own Parsortix system, ANG-002, and that the harvested CTCs could then be subjected to FISH analysis to determine their HER-2 status.
Kathryn B Becker, franchise director oncology and companion diagnostics at Abbott, said: "The PathVysion HER-2 DNA FISH Probe kit is reliable and accurate in tissue biopsy samples and the Parsortix system may unlock the potential for PathVysion use in a simple blood test."
The firm's founder and chief executive, Andrew Newland, added, "Following our FDA studies, we hope to be able to work with Abbott to extend PathVysion use into routine blood test analysis as an important downstream application of the Parsortix system in breast cancer. Use of ANGLE's Parsortix system would for the first time enable established tissue biopsy techniques to be used for breast cancer on cancer cells obtained from a simple blood test protecting patients from invasive procedures and improving their care whilst at the same time reducing healthcare costs."
As of 1040 GMT, shares had retreated 6.41% to 43.05p.
Fluorescence in situ hybridisation analysis, or FISH, is a form of investigating the cancer cells used with solid tissue biopsy to help select treatment and is one of Angle's exploratory end-points for its study into metastatic breast cancer.
Angle hopes to demonstrate that circulating tumour cells (CTCs) can be harvested from the blood of metastatic breast cancer patients using its own Parsortix system, ANG-002, and that the harvested CTCs could then be subjected to FISH analysis to determine their HER-2 status.
Kathryn B Becker, franchise director oncology and companion diagnostics at Abbott, said: "The PathVysion HER-2 DNA FISH Probe kit is reliable and accurate in tissue biopsy samples and the Parsortix system may unlock the potential for PathVysion use in a simple blood test."
The firm's founder and chief executive, Andrew Newland, added, "Following our FDA studies, we hope to be able to work with Abbott to extend PathVysion use into routine blood test analysis as an important downstream application of the Parsortix system in breast cancer. Use of ANGLE's Parsortix system would for the first time enable established tissue biopsy techniques to be used for breast cancer on cancer cells obtained from a simple blood test protecting patients from invasive procedures and improving their care whilst at the same time reducing healthcare costs."
As of 1040 GMT, shares had retreated 6.41% to 43.05p.
Related share prices |
---|
Angle (AGL) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price